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Aim of the study: To assess influencing
factors and main health-related quali-
ty of life (HRQoL) issues in patients 
with cancers of the oesophago-gastric
region using the European Organization
for Research and Treatment of Cancer
(EORTC) quality of life questionnaire Core
30 (QLQ-C30) and its oesophago-gastric
module (QLQ-OG25).
Material and methods: Patients were
qualified for this study based on the his-
tological confirmation of oesophageal,
oesophago-gastric or gastric cancers.
Each patient filled out the Polish version
of the EORTC QLQ-C30, the QLQ-OG25
module and a personal questionnaire.
Patients were divided into groups based
on gender, age, treatment intention,
tumour localization, working status and
level of education.
Results: Our study included 112 patients
– 39 women (35%) and 73 men (mean
age ± SD; 60.2 ±10.9). Thirty-five patients
(31.3%) completed the questionnaires
twice. Eighty-four (75%) patients had
gastric cancer (GC), twenty-six (23.2%)
oesophageal cancer (OC) and two (1.8%)
cancer of the oesophago-gastric junction
(OGJC). Eighty (71.4%) patients under-
went surgical treatment prior to either
chemo-, radio- or chemoradiotherapy. The
Global Health Status scale of the QLQ-
C30 inversely correlated with all the oth-
er QLQ-C30 and QLQ-OG25 symptom
scales (r = –0.26 to –0.61; p < 0.05).
Conclusions: The main HRQoL prob-
lems of Polish OC, OGJC and GC patients
are fatigue, insomnia, anxiety, and
appetite and weight loss. Older age,
receiving palliative treatment, having gas-
tric cancer, being on retirement and hav-
ing lower education are factors associ-
ated with higher symptom scores (worse
symptoms) and thus poorer HRQoL.
Key words: cancer, oncology, quality of
life, QLQ-OG25, QLQ-C30, oesophago-
gastric.
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Introduction
Over the last three decades the epidemiology of oesophageal and gastric
cancers has demonstrated significant changes [1]. In Poland cancers of the
oesophagus (OC) and the oesophago-gastric junction (OGJC) are rare – below
2% of all malignant neoplasms [2]. In men oesophageal cancer is the 10th cause
(2.3%) of cancer-related deaths. On the other hand, gastric cancers are still
fairly common in Poland and constitute 5.7% and 3.4% of all malignant neo-
plasms in Polish men and women respectively. Gastric cancer remains the 3rd
(7.4% in men) and 5th (5.5% in women) cause of cancer-related deaths [3]. Thus
GC in Poland still represents a huge social and oncological problem.
Worldwide the incidence of OC and gastric cardia cancers is increasing, while
the incidence of non-cardia adenocarcinomas of the stomach is decreasing
[1]. Health-related quality of life (HRQoL) measurement is an important com-
ponent of the assessment of cancer patients, including patients with OC, OGJC
and gastric malignancies. Having in mind the number of people with
oesophago-gastric cancers, we should understand that HRQoL problems in
this group of patients currently represent a major challenge, firstly, because
of the nature of the disease, and secondly, because of the number of people
suffering from oesophago-gastric region cancers. Not only is HRQoL an impor-
tant outcome measurement in everyday oncological practice, but also it is more
and more commonly taken into account as one of the endpoints in clinical
trials, providing a lot of information about the state of our patients [4, 5]. For
some patients, especially with metastatic disease, it is the most important
thing, even more important than prolonging life. That is why it is imperative
to get to know the main HRQoL issues which oesophago-gastric cancer patients
have to face every day. This knowledge will help physicians meet the needs
of their cancer patients. There are studies stating that by simply measuring
HRQoL also the patient-physician communication may be improved [6]. 
Quality of life questionnaires (QLQ) for measuring HRQoL in cancer
patients are created by the European Organization for Research and Treat-
ment of Cancer (EORTC). There are questionnaires designed to measure HRQoL
in OC and GC patients. The QLQ-C30 is the core questionnaire and there are
additional modules that are meant to be used with it [7]. Those are the QLQ-
STO22, specific for gastric cancers [8]; the QLQ-OES18, specific for oesophageal
cancers [9]; and the QLQ-OG25 (created by combining the corresponding ques-
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tions from the previous two), specific for oesophago-gastric
cancers [10]. By using the QLQ-OG25 instead of two sepa-
rate questionnaires, one can avoid the existing overlapping
in HRQoL issues between oesophageal and gastric cancer
patients. This has decreased the number of questions the
patient has to answer during the interview. All of the ques-
tionnaires have been translated and validated into many lan-
guages and their Polish versions are available from the EORTC
[10, 11]. Our group has translated and validated the Polish ver-
sion of the QLQ-OG25 module [12].
The aim of this study was to assess the influencing fac-
tors and main health-related quality of life issues in patients
with cancers of the oesophago-gastric region using the EORTC
QLQ-C30 and its QLQ-OG25 module.
Material and methods
Patients
In this study patients were recruited prospectively
between January 2011 and May 2012. The recruitment
process took place at the Department of Clinical Oncology
at the University Hospital in Krakow. Patients were eligible
if they had a histologically confirmed diagnosis of oesophageal
or gastric cancer, including neoplasms located at the oesoph-
agogastric junction. Location of the tumour was reconfirmed
on the basis of computed tomography (CT). All histological
types of OC, GC and OGJC were included in the study.
Patients included in the study were classified into groups
based on gender (female vs. male), age (below vs. above or
equal to 60 years of age), treatment intention (curative vs.
palliative), tumour localization (oesophagus vs. stomach) and
working status (employed vs. retired/pensioner).
Patients were interviewed during their visits at the out-
patient clinic or during their stay at the ward. The second inter-
view took place after a minimum of two weeks counting from
the first interview. During the interview each patient com-
pleted the Polish version of the EORTC QLQ-C30, the QLQ-
OG25 module and a personal questionnaire. Clinical histo-
ry and physical examination were registered for all patients.
Exclusion criteria included lack of consent to participate
in the study, inability to understand or complete the ques-
tionnaires and presence of concurrent malignancies. There
were no restrictions as to gender or age. All patients gave
their informed consent to participate in this study. The re -
search protocol was approved by the Jagiellonian Universi-
ty Ethics Committee (registry KBET/250/B/2011).
Translation and pilot testing
The Polish version of the EORTC QLQ-C30 (version 3.0) was
previously translated. The translation process of the EORTC
QLQ-OG25 Polish version was authorized by the EORTC. Items
deriving from the Polish versions of the QLQ-STO22 and the
QLQ-OES18 were used in an unchanged state. The remain-
ing items were translated according to the official EORTC
guidelines [13].
The translated, initial version of the QLQ-OG25 was pilot-
tested on 25 Polish patients with OC, OGJC or GC. Their com-
ments were analyzed and minor language changes were made
to the initial translation. This version was once again tested
on 15 additional patients. After this phase the final transla-
tion of the Polish version of the QLQ-OG25 was obtained and
approved by the EORTC Quality of Life Department.
Questionnaires
The QLQ-C30 is a 30-item questionnaire comprised of
a global health status, five multi-item functional scales, three
multi-item symptom scales, and six symptom single items.
The QLQ-OG25 is a 25-item module comprised of six mul-
ti-item scales: dysphagia, eating restriction, reflux, odynopha-
gia, pain and discomfort, and anxiety. In addition to the six
multi-item scales the QLQ-OG25 has 10 single items. High-
er scores indicate worse symptomatic problems.
All of the QLQ-C30 and the QLQ-OG25 multi-item scales
and single items were scored on a 1 to 4 point Likert scale
(“not at all”, “a little”, “quite a bit”, “very much”), apart from
items 29 and 30 of the QLQ-C30, which were scored on a 1 to
7 point scale. Items 29 and 30 comprise the global health sta-
tus. Detailed information on how to score the EORTC ques-
tionnaires can be found in the QLQ-C30 scoring manual and
its addendum [14].
Statistical analysis
Statistical analysis was conducted using  Statistica 10.0
PL computer software by StatSoft Poland. Scores for multi-
item functional or symptom scales and for single items were
calculated by linear transformation of raw scores into a 0-
100 score, with 100 representing the best global health, func-
tional status or worst symptoms – depending on the mea-
suring property of each multi-item or single-item scale, as
described by the EORTC [14, 15]. To analyse the data we used
elements of descriptive statistics (mean, standard deviation,
percentage distribution).
Group comparison was used to assess the differences in
HRQoL issues between known groups. Known groups used
in this study were: gender (female vs. male), age (below vs.
above or equal to 60 years of age), treatment intention (cura-
tive vs. palliative), tumour localization (oesophagus vs. sto -
mach), working status (employed vs. retired/pensioner) and
level of education (elementary vs. high school vs. vocation-
al vs. university). Differences between groups were tested
with ANOVA, t-test and Mann-Whitney tests as appropriate.
Spearman correlation analysis was performed to explore
the relationship between scales of the QLQ-C30 and the QLQ-
OG25.
A subset of patients completed the questionnaires twice
(n = 35) to evaluate whether HRQoL issues can change 
over a short period of time. The significance level was set at
p < 0.05.
Results
Patient characteristics
A total of 112 patients were recruited into the study – 
39 women (35%) and 73 men. Mean age of the group was
60.2 years ± standard deviation (SD) of 10.9 years. Eighty-
four patients had gastric cancer, twenty-six oesophageal can-
cer and two cancer of the oesophago-gastric junction.
Patients' clinical and demographic data are presented in Table
1. Eighty (71.4%) patients underwent surgical treatment pri-
or to either chemo-, radio- or chemoradiotherapy.
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No patients rejected taking part in the study. All 112 pa -
tients answered both the QLQ-C30 and the QLQ-OG25. Thir-
ty-five patients were selected to complete the questionnaires
a second time after a minimum of 2 weeks following the first
interview.
Main health-related quality-of-life issues
When taking into account the whole patient group the
main HRQoL issues (basing on the QLQ-C30) were Fatigue
(49/100 points), Insomnia (42.7/100 points), Appetite Loss
(41.7/100 points) and Role Functioning (40.1/100 points). The
scale assessing Diarrhoea (16.4/100 points) had the small-
est impact on the overall HRQoL. 
Based on the QLQ-OG25 the scales assessing Anxiety
(58.3/100 points), Weight Loss (45.5/100 points), Body
Image (43.6/100 points) and Eating Restriction (37.6/100 points)
had the biggest impact on the overall HRQoL. The scale assess-
ing Trouble Talking (6.9/100 points) had the smallest impact
on the overall HRQoL.
Group comparison
Comparing overall scores from the first and second in ter-
view, one can say that HRQoL in patients with OC, OGJC and
GC does not change over a short period of time (p > 0.05).
Comparison by gender shows that scales and items dis-
tinguishing between sexes are Pain (31.8 vs. 20; p = 0.0223),
Diarrhoea (22 vs. 4.8; p = 0.0076), Odynophagia (22.5 vs. 11.1;
p = 0,0144) (men having significantly higher scores) and Hair
Loss (10.2 vs. 41.6; p = 0.0010) (women having significant-
ly higher scores).
Known group comparison by age is shown in Table 2.
Scales and items that distinguish (p < 0.05) between age
Table 1. Patients’ demographic and clinical data
Overall Curative treatment Palliative treatment
(n = 112) (n = 52) (n = 60)
Gender (%)
Female 39 (35%) 19 (36.5%) 20 (33.3%)
Male 73 (65%) 33 (63.5%) 40 (66.7%)
Age (SD) 60.2 (10.9) 59.8 (9.5) 61.2 (12.5)
Cancer site (%)
Oesophagus 26 (23.2%) 8 (15.3%) 18 (30%)
Stomach 84 (75%) 42 (81%) 42 (70%)
Oesophago-gastric junction 2 (1.8%) 2 (3.7%) 0
Education (%)
Elementary 20 (17.9%) 10 (19.2%) 10 (16.7%)
High school 28 (25%) 12 (23.1%) 16 (26.7%)
Vocational 46 (41.1%) 20 (38.5%) 26 (43.3%)
University 18 (16%) 10 (19.2%) 8 (13.3%)
Employment (%)
Full time/part time 63 (56.3%) 40 (77%) 23 (38.3%)
Retired/Pensioner 49 (43.7%) 12 (23%) 37 (61.7%)
SD – standard deviation
Table 2. Group comparison by age. Only statistically significant data are shown
Age <60 Age ≥ 60
Scale/Item n Mean SD n Mean SD p-value
Physical Functioning 53 45.8 13.7 59 61.8 27.7 0.0002
Fatigue 53 41.9 21.4 59 55.2 26.3 0.0043
Nausea and Vomiting 53 8.3 12.2 59 30.0 31.8 < 0.0001
Pain 53 20.0 27.1 59 35.4 30.6 0.0059
Appetite Loss 53 28.9 32.4 59 52.9 38.6 0.0006
Eating Restriction 53 26.9 25.3 59 47.1 27.5 0.0001
Pain and Discomfort 53 15.0 21.6 59 31.4 31.7 0.0020
SD – standard deviation
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groups are Physical Functioning, Fatigue, Nausea and Vom-
iting, Pain, Appetite Loss, Eating Restriction, and Pain and Dis-
comfort. Overall older age was associated with higher
symptom scores.
Known group comparisons by treatment intention
showed that patients in the curative intention group versus
patients in the palliative treatment group present lower scores
(less symptoms) on the Physical Functioning (25.6 vs. 42; 
p = 0.0147), Fatigue (40 vs. 56.8; p = 0.0058), Insomnia (34.4
vs. 50; p = 0.0372) and Appetite Loss (30 vs. 52; p = 0.0183)
scales. No significant differences between the curative and
the palliative treatment group were noted in any of the scores
of the QLQ-OG25 scales or items.
Table 3 presents mean scores according to tumour location.
As for the QLQ-C30, scales that distinguished (p < 0.05) between
the two groups were Global Health Status and Role Functioning.
Single items of the QLQ-C30 that distinguished between the
two groups were Pain, Dyspnoea, Insomnia and Appetite Loss.
As for the QLQ-OG25, scales that distinguished between the
two groups were Dysphagia, Eating Restriction, and Odynopha-
gia. Single items of the QLQ-OG25 that distinguished between
the two groups were Eating with Others, Trouble Swallowing
Saliva, Trouble with Coughing, Trouble with Talking, Choking
when Swallowing and Weight Loss.
When scores were calculated by working status (Table 4)
both the QLQ-C30 and the QLQ-OG25 showed significantly
lower scores (less symptoms) in patients who are still pro-
fessionally active.
Comparing patient scores by level of education (elementary
vs. high school vs. vocational vs. university) showed that
Table 3. Group comparison by tumour location. Only statistically significant data are shown
Stomach Oesophagus
Scale/Item n Mean SD n Mean SD p-value
Global Health Status 84 63.6 42.3 26 41.2 43.9 0.0212
Role Functioning 84 59.0 37.0 26 35.3 31.4 0.0039
Pain 84 41.0 30.9 26 24.7 28.8 0.0187
Dyspnoea 84 51.3 42.2 26 19.6 27.6 0.0005
Insomnia 84 61.5 18.5 26 37.9 30.6 < 0.0001
Appetite Loss 84 61.5 30.0 26 36.6 37.9 0.0008
Dysphagia 84 49.1 33.7 26 19.2 24.9 < 0.0001
Eating Restriction 84 54.2 20.9 26 33.8 28.4 0.0001
Odynophagia 84 32.0 25.1 26 15.7 25.0 0.0046
Eating with Others 84 38.9 37.2 26 9.3 20.3 0.0002
Trouble Swallowing Saliva 84 44.4 38.5 26 5.8 17.1 < 0.0001
Trouble with Coughing 84 55.6 38.5 26 13.5 20.1 < 0.0001
Trouble Talking 84 25.0 37.9 26 2.6 11.2 0.0037
Choking when Swallowing 84 27.8 31.3 26 5.8 15.8 0.0008
Weight Loss 84 63.9 33.2 26 41.2 36.9 0.0037
SD – standard deviation
Table 4. Group comparison by working status. Only statistically significant data are shown
Working Retired
Scale/Item n Mean SD n Mean SD p-value
Physical Functioning 63 42.5 17.7 49 31.2 28.1 0.0128
Fatigue 63 42.6 23.2 49 57.6 24.9 0.0014
Appetite Loss 63 31.5 34.2 49 55.6 38.1 0.0006
Constipation 63 18.9 25.5 49 40.5 39.9 0.0007
Dysphagia 63 17.0 23.1 49 34.9 32.8 0.0010
Eating Restriction 63 30.3 25.8 49 47.0 28.7 0.0014
Pain and Discomfort 63 17.1 23.4 49 32.1 32.4 0.0053
Dry Mouth 63 25.9 29.9 49 44.1 36.4 0.0044
Trouble with Coughing 63 15.7 28.2 49 28.6 29.7 0.0207
SD – standard deviation
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patients with university level education cope better with pain
(Pain scale of the QLQ-C30) than patients with less educa-
tion (p = 0.0482). Scores from other scales presented no sig-
nificant differences in HRQoL associated with level of edu-
cation (p > 0.05) but a trend was observed suggesting that
higher education is associated with lower symptom scores.
Correlations between the QLQ-C30 
and the QLQ-OG25
The Global Health Status scale of the QLQ-C30 inverse-
ly correlated with all the other QLQ-C30 and QLQ-OG25 symp-
tom scales (r= –0.28 to –0.61; p < 0.05). An especially strong,
inverse correlation was noted between the Global Health Sta-
tus and Fatigue scales (r = –0.61; p < 0.0001). 
Strong correlations were also noted between the Nausea
and Vomiting scale of the QLQ-C30 and the Dysphagia and
Eating Restriction scales of the QLQ-OG25 (r = 0.63 and 
r = 0.65 respectively; p < 0.0001).
Three scales of the QLQ-OG25 correlated strongly with each
other – Dysphagia, Eating restriction and Odynophagia 
(r = 0.62-0.75; p < 0.0001).
Discussion
This study presents influencing factors and main HRQoL
issues in oesophago-gastric cancer patients as measured by
EORTC tools – the QLQ-C30 and the QLQ-OG25.
Measuring HRQoL is becoming an important outcome in
clinical trials and daily clinical practice. Several studies
have already used patient-reported outcome measures to
assess HRQoL in patients with oesophageal, gastric and
oesophago-gastric junction cancers [16-18].
Taking into account the obtained results, firstly we
should remember that cancer patient HRQoL problems should
not be viewed in a short-term perspective. As we can see,
a two to four week period is not enough to observe signif-
icant changes in HRQoL.
Our study shows that women tend to experience less severe
(or admit to experiencing less severe) symptoms than men.
This is especially visible in scales such as Pain, Diarrhoea and
Odynophagia. Our results stand in contradiction to those
obtained by van der Schaaf et al. [19]. We lack a good expla-
nation as to why such gender-dependent symptom changes
exist. For example, laboratory studies conducted thus far on
humans have showed no significant differences in pain per-
ception among men and women [20]. On the other hand,
women, compared to men, seem to focus more on appear-
ance issues such as hair loss, which is consistent with the cul-
turally based idea of women wanting to feel more visually
attractive than men. Similar gender-related differences in EORTC
questionnaire scale scores were noted in other studies [21].
Age had a substantial impact on the amount and sever-
ity of symptoms. The overall trend was that older age was
associated with higher symptom scores, but not all scales
achieved statistical significance. We have found this to be
consistent with other HRQoL studies [19, 22].
When comparing HRQoL by tumour location, patients with
stomach cancer consistently present higher symptom scores
(higher severity of symptoms), even when it comes to symp-
toms specific for oesophageal cancer such as “Trouble Swal-
lowing Saliva” or “Choking when Swallowing”. This partially
stands in contradiction to data presented by Onate-Oceana
et al. [23], which shows that as far as the above mentioned
symptoms are concerned, they are more specific for
oesophageal cancer patients than for gastric cancer patients.
It is impossible to argue which type of cancer would cause more
severe symptoms. This relies rather on the stage of the dis-
ease, not the disease type.
When taking into account professional activity, we
observed a trend that patients remaining professionally active
present less severe symptoms than patients on retirement.
This is not so easily explained. First of all, in the case of our
study it is impossible to determine whether being profes-
sionally active prevents development of severe symptoms
or whether the development of severe symptoms forces
a patient to retire. Secondly, our “retired patient” group has
a higher mean age and that can also contribute to increased
symptom severity as described earlier. Hence the difficulties
in establishing the correct chain of events that creates the
base for more severe symptoms to develop in patients on
retirement. Nevertheless, our findings concerning the role
of professional activity among cancer patients are consis-
tent with literature data [24].
Analysing the obtained correlations we can see that Fatigue
is the factor with the strongest impact on overall health sta-
tus. We think it is so because fatigue, at least in our cancer
patient group, was the symptom most often reported and
also associated with the highest number of additional
problems. Other factors that most significantly affected the
health status were Appetite loss and Eating restriction. All
three of those elements – Fatigue, Appetite loss and Eating
restriction – are related to the cachexia-anorexia syndrome.
Studies conducted among patients with malignancies
including cancers of the upper gastrointestinal tract showed
that the severity of cachexia-anorexia has a huge impact on
the quality of life in these patients [25, 26].
The strong correlation between the Dysphagia, Eating
restriction and Odynophagia scales can be explained by the
fact that patients often merged these three problems into
one, even when supplied with additional information from
the interviewer.
What is interesting, patients attribute most of their HRQoL
issues to problems due to fatigue, anxiety, insomnia, body
image, appetite and weight loss. This is partially consistent
with other studies that show that especially anxiety is a major
problem among cancer patients [23].
Anxiety, insomnia, appetite loss and body image can be
considered more as psychological issues than purely medical
ones. Symptoms such as dysphagia, reflux, odynophagia, nau-
sea and vomiting are ranked lower and do not contribute as
much to the overall HRQoL score as psychological problems.
This points to the fact that Polish cancer patient care should
focus even more on patient psychological problems.
To allow for a comparison of the data from this manuscript
(results from a single-centre study) to the general popula-
tion, certain comments, on the subject of study group char-
acteristics, are needed. A study by Krstev et al. [27], conducted
on 443 Polish patients with newly diagnosed gastric cancer,
shows similar data in regard to gender distribution (35.7%
women) and mean age (mean age of 63.8) of participants.
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This points to the fact that the results obtained in this study
can be related to the general Polish population. Though the
incidence of GC in Poland is predicted to decrease [28] in the
next 12 years, this cancer will still be more common in men
then in women. The fall in the incidence of GC will be notably
slower in the group of people older then 65 years [28]. Thus,
this age group will remain the dominant one among Polish
GC patients. The GC gender percentage distribution is not
predicted to change [28].
In conclusion, the main HRQoL problems of Polish OC, OGJC
and GC patients are fatigue, insomnia, anxiety, appetite and
weight loss. Polish cancer patients report fewer organic HRQoL
issues then their western European counterparts. Older age,
receiving palliative treatment, having a cancer of the stom-
ach, being on retirement and having lower education are fac-
tors associated with higher symptom scores (worse symp-
toms) and thus poorer health-related quality-of-life.
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